Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SPY003 in adults with moderate to severe ulcerative colitis
NL-OMON60695Phase 2Withdrawn
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SPY003 in autoimmune colitis (2 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoints: Change in RHI from baseline at Week 12 and Clinical remission at Week 12. Planned start Oct 2025; status: withdrawn.
02
Drugs
SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60695.